Category Press Releases

Bristol Myers Squibb Announces Positive Phase 3 Results for Sotyktu in Psoriatic Arthritis

Bristol Myers Squibb has announced positive results from arthritis two pivotal Phase 3 trials, POETYK PsA-1 (IM011-054) and POETYK PsA-2 (IM011-055), which evaluated the efficacy and safety of Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA). Both trials met…

Read MoreBristol Myers Squibb Announces Positive Phase 3 Results for Sotyktu in Psoriatic Arthritis

Regeneron Advances Factor XI Antibodies to Phase 3 After Positive Phase 2 Results

Regeneron Pharmaceuticals has announced positive Phase 2 results for two innovative monoclonal antibodies targeting distinct domains of Factor XI. REGN7508, designed to maximize anticoagulant activity while minimizing bleeding risk, targets the catalytic domain, while REGN9933, aimed at patients with the…

Read MoreRegeneron Advances Factor XI Antibodies to Phase 3 After Positive Phase 2 Results

Roche Prasinezumab Shows Potential in Early Parkinson’s Despite Phase IIb Miss

Roche has announced results from the Phase IIb PADOVA study investigating prasinezumab in 586 individuals with early-stage Parkinson’s disease. Participants received treatment for a minimum of 18 months while maintaining stable symptomatic therapies. The study’s primary endpoint, time to confirmed…

Read MoreRoche Prasinezumab Shows Potential in Early Parkinson’s Despite Phase IIb Miss

Viatris Publishes Phase 2b CARE Study Data on Cenerimod in Lancet Rheumatology

Viatris announced the publication of Phase 2b CARE study results evaluating the efficacy and safety of cenerimod in adults with moderate-to-severe systemic lupus erythematosus (SLE). The findings, published in Lancet Rheumatology, demonstrated that cenerimod 4 mg provided clinically meaningful and…

Read MoreViatris Publishes Phase 2b CARE Study Data on Cenerimod in Lancet Rheumatology

Teva and Sanofi Announce Positive Phase 2b Results for Duvakitug in Ulcerative Colitis and Crohn’s Disease

Teva Pharmaceuticals and Sanofi today announced that the Phase 2b RELIEVE UCCD study of duvakitug (TEV’574/SAR447189), an anti-TL1A monoclonal antibody, met its primary endpoints for the treatment of moderate-to-severe ulcerative colitis (UC) and Crohn’s disease (CD). The study, which evaluated…

Read MoreTeva and Sanofi Announce Positive Phase 2b Results for Duvakitug in Ulcerative Colitis and Crohn’s Disease

Aflibercept 8 mg Phase III Study Shows Vision Gains with Extended Treatment Intervals in Retinal Vein Occlusion

Bayer announced positive topline results from the global Phase III QUASAR study, which evaluated the efficacy and safety of aflibercept 8 mg in patients with macular edema following retinal vein occlusion (RVO), including central, branch, and hemiretinal vein occlusion. The…

Read MoreAflibercept 8 mg Phase III Study Shows Vision Gains with Extended Treatment Intervals in Retinal Vein Occlusion

EYLEA HD 8 mg Phase 3 Trial Shows Improved Vision with Extended Dosing in Macular Edema

Regeneron Pharmaceuticals, Inc announced today that the Phase 3 QUASAR trial investigating EYLEA HD® (aflibercept) Injection 8 mg has successfully met its primary endpoint. The trial evaluated the treatment of macular edema following retinal vein occlusion (RVO), including central, branch,…

Read MoreEYLEA HD 8 mg Phase 3 Trial Shows Improved Vision with Extended Dosing in Macular Edema